ARCHIVES

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

This article is from The Cancer Letter archive.

Vol. 29 No. 41 | November 7, 2003

Download PDF Visit The Full Archive

Related Articles

Rauscher Says He May Leave, But Will Stay Through June

February 6, 1976

NIH Considering Intramural NRSA, NCI Advisors Not Enthusiastic

February 17, 1984

FDA Approves Abraxane For Second-Line Treatment Of Metastatic Breast Cancer

January 28, 2005

ASCO, COA Present Plans For Cancer CareBeyond the Fee-For-Service Pay Structure

January 24, 2014

CCIRC Loses Policy Making, Protocol Review

September 26, 1975

In Brief: Congressmen Press Or More Exploratory Grant Money: Murphy Reelected By UICC

August 6, 1976